Wednesday 1 May | |
Anexo Group PLC | Full Year Results |
Cambridge Cognition Holdings PLC | Full Year Results |
Computacenter PLC | Trading Statement |
Georgia Capital PLC | Q1 Results |
GSK PLC | Q1 Results |
Haleon PLC | Trading Statement |
HSS Hire Group PLC | Full Year Results |
Intelligent Ultrasound Group PLC | Full Year Results |
Maintel Holdings PLC | Full Year Results |
Next PLC | Trading Statement |
Smith & Nephew PLC | Trading Statement |
Thursday 2 May | |
Endeavour Mining PLC | Q1 Results |
First Tin PLC | Trading Statement |
Hiscox Ltd | Trading Statement |
International Personal Finance PLC | Trading Statement |
Kerry Group PLC | Trading Statement |
Lancashire Holdings Ltd | Trading Statement |
Melrose Industries PLC | Trading Statement |
NAHL Group PLC | Full Year Results |
Reach PLC | Trading Statement |
Shell PLC | Q1 Results |
Smiths News PLC | Half Year Results |
Smurfit Kappa Group PLC | Trading Statement |
Spectris PLC | Trading Statement |
Standard Chartered PLC | Q1 Results |
TI Fluid Systems PLC | Q1 Results |
Friday 3 May | |
InterContinental Hotels Group PLC | Trading Statement |
Mondi PLC | Trading Statement |
Trainline PLC | Full Year Results |
Monday 6 May | |
no events scheduled | |
Tuesday 7 May | |
Arecor Therapeutics PLC | Full Year Results |
BP PLC | Q1 Results |
Ebiquity PLC | Full Year Results |
IWG PLC | Trading Statement |
Kosmos Energy Ltd | Q1 Results |
MaxCyte Inc | Q1 Results |
Trident Royalties PLC | Trading Statement |
Vaalco Energy Inc | Q1 Results |
Comments and questions to newsroom@alliancenews.com | |
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
Copyright 2024 Alliance News Ltd. All Rights Reserved. |
Cambridge Cognition hoping to ride coat-tails of Biogen Alzheimer's programme
(Sharecast News) - Cambridge Cognition announced on Friday that, Following a consultation with the US Food and Drug Administration (FDA), Biogen and Eisai have announced plans to pursue regulatory approval for 'aducanumab', which would be the first therapy to tackle clinical decline in early Alzheimer's disease.
Read more